Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of catalpol in preparation of medicine for preventing and curing or delaying myasthenia and/or amyotrophia

A technology for muscle weakness and muscle atrophy, which is applied in drug combinations, pharmaceutical formulas, and muscular system diseases. It can solve the problems of diabetic myopathy with little curative effect and no cause and target of diabetic myopathy, so as to delay muscle weakness. and/or muscle atrophy, improvement of decreased exercise capacity, and improvement of muscle weakness

Inactive Publication Date: 2017-01-04
CHINA PHARM UNIV
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Factors causing diabetic myopathy include diabetic microangiopathy, metabolic disorder, diabetic neuropathy, and genetic factors. However, the exact cause and target of diabetic myopathy have not been found so far. In addition, there is currently no drug that can cure diabetes. purpose to prevent or delay diabetic myopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of catalpol in preparation of medicine for preventing and curing or delaying myasthenia and/or amyotrophia
  • Application of catalpol in preparation of medicine for preventing and curing or delaying myasthenia and/or amyotrophia
  • Application of catalpol in preparation of medicine for preventing and curing or delaying myasthenia and/or amyotrophia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The pharmacodynamics evaluation of catalpol treating myasthenia caused by late stage diabetes mellitus, the specific method is as follows: buy 12 db / db (C57BL / KsJ) mice, 6 C57BL / 6NCrlVr mice, wild-type C57BL / 6NCrlVr mice as The normal control NC group (n=6), db / db (C57BL / KsJ) mice were randomly divided into two groups according to body weight stratification, named respectively as db / db model group (n=6) and catalpol treatment group (200mg / kg, n=6) The specific grouping and administration methods are as shown in Table 1:

[0021] Table 1. The specific grouping of experimental mice and the dosage and administration method

[0022] group number of animals Method of administration Dosage Time point of first administration (8 weeks old) NC group 6 Equal volume of distilled water 0.1ml / 10g 57d db / db model group 6 Equal volume of distilled water 0.1ml / 10g 57d catalpol treatment group 6 catalpol 200mg / kg 57d

[0023] Admi...

Embodiment 2

[0036] Catalpol treatment of HFD-induced early diabetes-induced pharmacodynamics evaluation, the specific method is as follows: 64 C57BL / 6NCrlVr mice were purchased, and the mice were randomly divided into 8 groups according to body weight, respectively NC control group 1 ( n=8), IFG model group (n=8), catalpol treatment group 1 (n=8), metformin treatment group 1 (n=8), NC control group 2 (n=8), IGT model group (n =8), catalpol treatment group 2 (n=8), metformin treatment group 2 (n=8). Except NC control group 1 and NC control group 2 were fed with normal feed RD (Nantong Trophy Feed Technology Co., Ltd.), and other groups were fed with high-fat feed HFD (TP24200, Nantong Trophy Feed Technology Co., Ltd.). After 6 weeks of HFD modeling, the success of the impaired fasting glucose regulation (IFG) model was verified. NC control group 1 (n=8), IFG model group (n=8), catalpol treatment group 1 (n=8), metformin treatment Group 1 (n=8) began to administer drugs, and each group was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal application of catalpol. Experiments find that catalpol can remarkably improve myasthenia and amyotrophia caused by diabetes and reverse the loss of I type muscle fibers in skeletal muscles due to diabetes. Results show that catalpol can enhance the holding power of the skeletal muscles, improve the reduced motor ability caused by diabetes, increase the total weight of the skeletal muscles as well as the weight of gastrocnemius muscles and soleus muscles, improve insulin resistance and reduce fasting blood glucose, thereby improving myasthenia and amyotrophia caused by diabetes. Accordingly, catalpol can be used for preventing and curing or delaying myasthenia and / or amyotrophia caused by diabetes. Catalpol can be extracted from traditional Chinese medicines and is cheap, safe, effective and easily available and has great market prospect accordingly.

Description

technical field [0001] The invention relates to a medical application of catalpol, which is used for preparing medicines for preventing or delaying muscle weakness and / or muscle atrophy caused by diabetes. Background technique [0002] Diabetes is a group of metabolic diseases characterized by hyperglycemia. Elevations in blood glucose result from defective insulin secretion or impaired biological action, or both. Early diabetes (Pre-diabetes) refers to the blood sugar is higher than the normal level, but has not yet reached the diagnostic level of diabetes, that is, the period of impaired glucose homeostasis. It is mainly divided into two stages: impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), and finally develops into diabetes. With the changes in people's diet structure and living habits, the incidence of diabetes is increasing year by year, and the mortality and disability rates are also increasing. According to incomplete statistics, as of 2012, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/02A61P21/00A61P3/10
CPCA61K31/7048A61P3/10A61P21/00A61P21/04A61P25/02
Inventor 江振洲徐登球王涛张陆勇俞沁玮张玲
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com